Jeremy Chadwick Sells 91,250 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 91,250 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $77.41, for a total transaction of $7,063,662.50. Following the transaction, the chief operating officer directly owned 61,202 shares of the company’s stock, valued at approximately $4,737,646.82. This trade represents a 59.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kymera Therapeutics Stock Performance

KYMR stock opened at $80.18 on Friday. The company has a 50 day moving average price of $80.05 and a two-hundred day moving average price of $70.43. The stock has a market capitalization of $6.55 billion, a P/E ratio of -21.79 and a beta of 2.20. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the previous year, the company earned ($0.88) earnings per share. The company’s revenue was down 60.8% on a year-over-year basis. Research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KYMR has been the subject of several analyst reports. JPMorgan Chase & Co. upped their target price on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Piper Sandler lifted their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Stephens boosted their price objective on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $108.00 target price on shares of Kymera Therapeutics in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $118.90.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Federated Hermes Inc. bought a new position in shares of Kymera Therapeutics during the third quarter valued at approximately $31,622,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kymera Therapeutics by 77.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock worth $1,007,000 after purchasing an additional 10,052 shares during the last quarter. Hudson Bay Capital Management LP boosted its position in Kymera Therapeutics by 362.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock valued at $1,309,000 after purchasing an additional 18,134 shares during the period. Candriam S.C.A. boosted its position in Kymera Therapeutics by 24.4% during the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after purchasing an additional 37,536 shares during the period. Finally, Frontier Capital Management Co. LLC grew its stake in Kymera Therapeutics by 272.7% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after buying an additional 359,847 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.